



Molecular Research of Triple-Negative Breast Cancer

Guest Editors:

Dr. Anna De Blasio

Department of Biological,
Chemical and Pharmaceutical
Sciences and Technologies
(STEBICEF), Laboratory of
Biochemistry, University of
Palermo, Viale delle Scienze, ed.
16, 90128 Palermo, Italy

Dr. Daniela Carlisi

Department of Biomedicine,
Neurosciences and Advanced
Diagnostics (BIND), Institute of
Biochemistry, University of
Palermo, Via del Vespro, 131,
90127 Palermo, Italy

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editors

Breast cancer is classified on the basis of histological and molecular variability; a subgroup equally heterogeneous is triple-negative breast cancer (TNBC), which shows lost expression of PR, ER and HER2/NEU receptors and a general molecular expression that confers it a particularly metastatic and invasive nature, drug resistance and poor prognosis. Therefore, several subtypes that actually have no specific molecular targets characterize TNBC and, consequently, a feature that makes it difficult to set a valid therapeutic strategy and so, to date, conventional chemotherapy is the only choice.

The Special Issue aims to collect recent results in this context, as:

- Genetic, epigenetic, transcriptional profiles;
- Description of proteomic features and/or biochemical pathways;
- Identification of cancer stem cells and their cross-talk with microenvironment; metabolic reprogramming;
- Effect induced in vitro/in vivo of any (or combination of) drugs;
- Triple-negative breast cancer immunity and metabolic reprogramming;
- Any evidence useful to suggest and define novel molecular target to challenge the aggressive character of TNBC.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding

Rehabilitation Hospital and

Massachusetts General Hospital,

Harvard Medical School, Boston,

MA 02114, USA

2. Department of Epidemiology,

Harvard T.H. Chan School of

Public Health, Boston, MA 02115,

USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)